Sofia Mastoraki, PhD, University of Texas MD Anderson Cancer Center, Houston, TX discusses her two posters from AACR 2022. The first poster focuses on single cell technologies which can be utilised to differentiate the risk of luminal A and luminal B patients in early-stage HR+/HER2- breast cancer via gene sequencing. This can both predict long-term outcomes and be used as an early prognostic tool before the initiation of FUV1 endocrine treatments. Her second poster discusses how cyclin E can act as a biomarker to identify patients susceptible to immunotherapy. Indeed, cyclin E drives changes early on in the mammary gland microenvironment – specifically epithelial cells – before tumor initiation and leads to hot tumor formation which can be targeted with immunotherapy. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, LA.